ClinicalTrials.gg
CompletedNCT01924962REVASCUpdated Nov 7, 2017

Recovery of Left Ventricular Function in Chronic Total Occluded Coronary Arteries

An interventional study of revascularisation in Coronary Heart Disease, sponsored by University Heart Center Freiburg - Bad Krozingen. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-07.

Sponsored by University Heart Center Freiburg - Bad Krozingen · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 years 2 months after the study started (first participant enrolled May 2008, registered Aug 2013).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
205
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 123 studies in Coronary Disease with a site in Germany — 9 open to participants now, 13 under way, 1 of them phase 3. Coronary Disease · Germany.

Enrollment
50th of 84
205 · median 322
Started
2008
with 11 others
No phase
25 of 123
2 open now
Registered
82nd of 123
by date

Among the 123 studies in Coronary Disease with a site in Germany, this one is the 50th largest by enrollment of the 84 interventional ones that give a count, is one of 12 that started in 2008, is one of 25 with no phase, and was the 82nd registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

9 of the 123 studies in Coronary Disease with a site in Germany are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 123 studies in Coronary Disease with a site in Germany, or all of them as a file.
02

Study summary

The study is a randomised comparison of recanalisation of chronic occluded coronary arteries with implantation of Sirolimus eluting stents and medical therapy. Myocardial function and scar-size are determinated by using magnetic resonance imaging. The study hypothesis is the superiority of medical therapy over revascularisation.

Read the detailed description

In the REVASC-study recovery of left ventricular function after recanalization of chronic total coronary occlusions (CTO) and implantation of sirolimus-eluting stents will be examined and compared to medical treatment. Extent of the scar, viable myocardium in the infarct zone and regional left ventricular function will be assessed by cardiac magnetic resonance. Patients with regional systolic left ventricular dysfunction of any degree in the supply territory of the CTO vessel will be randomized to either recanalization of the occluded coronary artery or to conservative therapy. It is of interest whether CTO patients will have an improvement in left ventricular function after late coronary reopening, regarding the high technical demands and costs of CTO recanalization.

03

Conditions studied

  • Coronary Heart Disease

Browse trials for

Keywords

  • chronic occlusion of coronary artery
  • left ventricular function
  • revascularisation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • chronic total occlusion with thrombolysis in myocardial infarction (TIMI) 0 flow (or distal capillary reflow) of a native coronary artery with an estimated reference vessel diameter of 2.5 to 4.0 mm
  • chronic total occlusion has more than 4 weeks duration
  • the target vessel has not previously been treated with percutaneous coronary intervention
  • the target vessel must be feasible for stent implantation
  • patient has stable or unstable angina pectoris or a positive functional study for ischemia
  • patient must be 18 years of age or older
  • female subjects of childbearing age must have a negative pregnancy test within 7 days before procedure
  • patient has been informed of the nature of the study and agrees to its
  • provisions ans has written as approved by the Ethics Committee
  • patient complies with all required post-procedure follow-up

Exclusion criteria

Exclusion Criteria:

  • a documented left ventricular function \< 30%
  • patient has a acute myocardial infarction (>3x normal creatine kinase (CK with presence of CK-MB) within 72 hours preceding the index procedure and CK has not returned to normal limits at the time of the procedure
  • patients with known or to aspirin, heparin, clopidogrel, stainless steel or contrast media that cannot be adequately been pre-medicated
  • patient has a count of \< 100000 cells/mm3 or > 700000 cells/m3, a white blood cell count of \< 3000 cells/mm3 or documented or suspected liver disease
  • patient has a history of bleeding diathesis or coagulopathy
  • patient has suffered a cerebrovascular accident or within the past 6 months
  • active peptic ulcer or upper gastrointestinal bleeding within the prior 6 months
  • patients has a co-morbidity (i.e. cancer or congestive heart failure) that may cause the patient to be non-compliant with the protocol, or is associated with limited life-expectancy (less than 2 years)
  • the target vessel contains intraluminal thrombus
  • the target vessel or lesson shows angiographic evidence of severe calcification
  • patient has contraindications to magnetic resonance imaging
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
205 participants (actual)

Study arms

  • No intervention
    medical therapy

    patients are treated with medical therapy only, intervention (stent) of other than (chronic occluded) target-vessel is allowed.

  • Active comparator
    revascularisation

    revascularisation and stent-implantation of chronic occluded coronary artery

    Device: revascularisation

Interventions

  • Devicerevascularisation

    revascularisation of chronic occluded coronary artery

    Also known as: Cypher-stent

06

What researchers measure

Primary outcomes

  1. Changes from baseline in regional left ventricular function at 9 months

    Improvement of the left ventricular function in the territory of the chronically occluded coronary artery assessed by magnetic resonance imaging before revascularisation and at 9 months post-procedure. For regional left ventricular analysis, wall thickening and systolic inward motion will be determined in 12 segments in all short axis slices by the modified centerline method.

    Time frame: 9 months

Secondary outcomes

  1. Change from baseline in global left ventricular function at 6 months

    Improvement of global left ventricular function (assessed by magnetic resonance imaging at baseline and 9 months post-procedure. For global left ventricular analysis, all short-axis slices from the apex to the base will be assessed. By planimetry of all short-axis views, left ventricular end-systolic volume (in milliliters), left ventricular end-diastolic volume (in milliliters), and ejection fraction (in percent) will be determined.

    Time frame: 6 months

  2. Changes from baseline in left ventricular volume at 6 months

    Changes in diastolic and systolic volume indices (assessed by magnetic resonance imaging at baseline and 9 months post-procedure)

    Time frame: 6 months

07

Study locations

1 site
  • Universitäts Herzzentrum Freiburg Bad Krozingen
    Bad Krozingen, Baden-Württemberg 79189, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2008 to primary completion in Aug 2016, 98 months.

Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 98 months is above that.

Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2013
First posted
Aug 19, 2013
StartActual
May 28, 2008
Primary completionActual
Aug 14, 2016
CompletionActual
Jun 16, 2017
Last update
Nov 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01924962
Lead sponsor
University Heart Center Freiburg - Bad Krozingen
Responsible party
Dr. Heinz Joachim Buettner (head of cath-lab department, University Heart Center Freiburg - Bad Krozingen) — Principal investigator
First posted
Aug 19, 2013
Start date
May 28, 2008
Primary completion
Aug 14, 2016
Completion
Jun 16, 2017
Last update
Nov 7, 2017

Study contacts

Heinz Joachim Buettner, MD
principal investigator · Universitaets-Herzzentrum Freiburg-Bad Krozingen, Clinics for Cardiology and Angiology II, D-79189 Bad Krozingen, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion